Lauren White
Directeur Financier/CFO chez IMMUNOGEN, INC.
Profil
Lauren A.
White is currently the Chief Financial Officer & Senior Vice President at ImmunoGen, Inc. Prior to this, she was the Treasurer, Chief Financial & Accounting Officer at C4 Therapeutics, Inc. from 2021 to 2023.
Before that, she was the VP, Global Head-Business Planning & Analysis at Novartis Institutes for Biomedical Research, Inc. Ms. White holds an MBA from Harvard Business School and an undergraduate degree from Wallace E Carroll School of Management.
Postes actifs de Lauren White
Sociétés | Poste | Début |
---|---|---|
IMMUNOGEN, INC. | Directeur Financier/CFO | 18/09/2023 |
Anciens postes connus de Lauren White
Sociétés | Poste | Fin |
---|---|---|
C4 THERAPEUTICS, INC. | Directeur Financier/CFO | 15/09/2023 |
Novartis Institutes for Biomedical Research, Inc.
Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Formation de Lauren White
Harvard Business School | Masters Business Admin |
Wallace E Carroll School of Management | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
C4 THERAPEUTICS, INC. | Health Technology |
Entreprise privées | 2 |
---|---|
Novartis Institutes for Biomedical Research, Inc.
Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA. | Commercial Services |
ImmunoGen, Inc.
ImmunoGen, Inc. BiotechnologyHealth Technology ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded on March 27, 1981 and is headquartered in Waltham, MA. | Health Technology |